AKT1 antibody
GTX110613
ApplicationsImmunoPrecipitation, Western Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
Product group Antibodies
TargetAKT1
Overview
- SupplierGeneTex
- Product NameAKT1 antibody
- Delivery Days Customer9
- Application Supplier NoteWB: 1:1000-1:10000. IHC-P: 1:100-1:1000. IP: 1:100-1:500. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
- ApplicationsImmunoPrecipitation, Western Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
- CertificationResearch Use Only
- ClonalityPolyclonal
- Concentration0.47 mg/ml
- ConjugateUnconjugated
- Gene ID207
- Target nameAKT1
- Target descriptionAKT serine/threonine kinase 1
- Target synonymsAKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA, RAC-alpha serine/threonine-protein kinase, AKT1m, PKB alpha, RAC-PK-alpha, protein kinase B alpha, proto-oncogene c-Akt, rac protein kinase alpha, serine-threonine protein kinase, v-akt murine thymoma viral oncogene homolog 1, v-akt murine thymoma viral oncogene-like protein 1
- HostRabbit
- IsotypeIgG
- Protein IDP31749
- Protein NameRAC-alpha serine/threonine-protein kinase
- Scientific DescriptionThe serine-threonine protein kinase encoded by the AKT1 gene is catalytically inactive in serum-starved primary and immortalized fibroblasts. AKT1 and the related AKT2 are activated by platelet-derived growth factor. The activation is rapid and specific, and it is abrogated by mutations in the pleckstrin homology domain of AKT1. It was shown that the activation occurs through phosphatidylinositol 3-kinase. In the developing nervous system AKT is a critical mediator of growth factor-induced neuronal survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating the serine/threonine kinase AKT1, which then phosphorylates and inactivates components of the apoptotic machinery. Multiple alternatively spliced transcript variants have been found for this gene. [provided by RefSeq]
- Storage Instruction-20°C or -80°C,2°C to 8°C
- UNSPSC12352203
References
- Vadhan A, Hou MF, Vijayaraghavan P, et al. CD44 Promotes Breast Cancer Metastasis through AKT-Mediated Downregulation of Nuclear FOXA2. Biomedicines. 2022,10(10). doi: 10.3390/biomedicines10102488Read this paper
- Cervellera C, Russo M, Dotolo S, et al. STL1, a New AKT Inhibitor, Synergizes with Flavonoid Quercetin in Enhancing Cell Death in A Chronic Lymphocytic Leukemia Cell Line. Molecules. 2021,26(19). doi: 10.3390/molecules26195810Read this paper
- Okabe S, Tanaka Y, Tauchi T, et al. Copanlisib, a novel phosphoinositide 3-kinase inhibitor, combined with carfilzomib inhibits multiple myeloma cell proliferation. Ann Hematol. 2019,98(3):723-733. doi: 10.1007/s00277-018-3547-7Read this paper
- Sikorski K, Mehta A, Inngjerdingen M, et al. A high-throughput pipeline for validation of antibodies. Nat Methods. 2018,15(11):909-912. doi: 10.1038/s41592-018-0179-8Read this paper
- Zhang Z, Zhong X, Xiao Y, et al. MicroRNA-296 inhibits colorectal cancer cell growth and enhances apoptosis by targeting ARRB1-mediated AKT activation. Oncol Rep. 2019,41(1):619-629. doi: 10.3892/or.2018.6806Read this paper
- Vazquez-Mellado MJ, Aguilar C, Rocha-Zavaleta L. Erythropoietin protects neuroblastoma cells against etoposide and vincristine by activating ERK and AKT pathways but has no effect in kidney cells. Life Sci. 2015,137:142-9. doi: 10.1016/j.lfs.2015.07.022Read this paper
- Lee KH, Lo HL, Tang WC, et al. A gene expression signature-based approach reveals the mechanisms of action of the Chinese herbal medicine berberine. Sci Rep. 2014,4:6394. doi: 10.1038/srep06394Read this paper
- Chen YJ, Cheng YJ, Hung AC, et al. The synthetic flavonoid WYC02-9 inhibits cervical cancer cell migration/invasion and angiogenesis via MAPK14 signaling. Gynecol Oncol. 2013,131(3):734-43. doi: 10.1016/j.ygyno.2013.10.012Read this paper





